Global Artificial Pancreas Systems Market, “By Devices (Threshold Suspend Device System, Non-Threshold Suspend Device System, Control To Range System, Control To Target System), By End User (Hospital, Clinics, Home Care, Ambulatory Center), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast is projected to reach USD 165.74 million by 2025, at a CAGR of 8.4% during the forecast period of 2018 to 2025.
Artificial pancreas system consists of continuous glucose monitor and insulin infusion pump and a controller to control and monitor the pump. The amount of insulin delivered in done by computer-controlled algorithm in a very sophisticated way. According to the study conducted by American diabetes association in the year 2017 around 1.25 million of the people are suffering from type 1 diabetes and around 40,000 new cases of the diabetes are been diagnosed every year. The other type of diabetes is type 2 diabetes which is more severe. In this the body is unable to metabolize glucose which in terms leads to hyperglycemia. This is now a days becoming more common in teens, young adults, children. Type 2 diabetes accounts for over all 90.0% of all diabetes cases worldwide.
In September 2016, Medtronic got an approval for artificial pancreas which was the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes making the work of patient easy by eliminating the need for continually monitoring insulin levels throughout each day.
Technological advancements in artificial pancreas systems are a major factor propelling the growth of the market. For instance, in May 2018Beta Bionics, Inc, received an approval from FDA to begin recruitment for home-use studies testing the insulin. This trail will be conducted on adults and children so that they can understand and develop and commercialize the world’s first autonomous bionic pancreas. Adults 18 years and above with type 1 diabetes will be recruited through Massachusetts general hospital and Stanford University. Children 6- 17 years suffering from type 1 diabetes will be recruited through nemours children’s health system, the Barbara Davis Center for diabetes at the university of Colorado, and Stanford University.
Novo Nordisk’s recently got an approval for fast-acting insulin called Fiasp and is equipped with iLet bionic pancreas system. Presently this fast acting insulin is been tested by the US-based multicenter, multi-arm, cross-over, clinical trial in adults with type 1 diabetes.
The global market for artificial pancreas system by the following sub-categories is presented
Increase in the prevalence of the diabetes:
According to national institute for health research, UK from total diabetic population around 10.0%-15.0% suffer from type 1 diabetes. Around 1.1 billion USD are spent on treatment of type 1 diabetes. According to the International Diabetes Federation, around 2.28 million people suffered from diabetes in the year 2015. And this number is expected to get double by 2050.
Type 1 diabetes is generally caused by genetic factor or by the environment factor. It is been observer that in India type 1 diabetes mellitus is on increase as type 2 diabetes mellitus. India has 3 new cases per 100,000 children of 0-14 years. A past 50 year ratio was calculated in Finland, and it was observed that the ratio of type 1 diabetes was chance from 10 per 100,000 to 60 per 100,000 children. 78,000 children under 15 years of age are estimated to develop type 1 diabetes yearly worldwide. 24.0% are form European region, and 23.0% are for south east Asian region.
46.0% of patients suffering from type 2 diabetes in India are under 40 according to the study conducted in 2014. India is known to be the diabetes capital of the world that is almost 50 million people suffers from type 2 diabetes. According to the world health organization around 3.4 million deaths are cause due to high blood sugar. And 80.0% of this occurs in low and middle income countries. And is estimated that this death rate will increase to double between 2016 to 2030. In 2010 the peoples suffering from type 2 diabetes were around 285 million and it is projected to increase to 438 million by 2030. In India this rate was 51 million in 2010 and is estimated tom increase to 87 million by 2030.
Hence with increasing diabetes population and with the ability of the artificial pancreas to achieve optimum blood sugar level as compare to conventional injections the artificial pancreas market is expected to achieve great heights in future.
Increasing demand of remote monitoring applications:
The food and drug organization is collaborating with private and government research organizations to improve the clinical studies and to speed the development for artificial pancreas devices.
According to a study conducted by the global diabetes community, it was found that artificial pancreas improves blood glucose control in type 2diabetes. A study was conducted on 40 adults in a hospital for 3 days. And the difference between the patients who were treated by artificial pancreas and those who were taking insulin was observed. And it was found that the patients who were treated with artificial pancreas achieved the optimal blood sugar level 60.0% of the time while those who were dependent on the conventional injections achieved the optimal blood sugar level 38.0% of times. This shows artificial pancreas works very effectively even in type 2 diabetes as compare to conventional injections.
This shows that artificial pancreas which is remote monitored can work effectively. And can obtain the optimum sugar level. By this people from type 1 and type 2 diabetes can monitored their sugar level very easily and effectively. Hence this market has a very strong platform in future.
Major market players in this market are Medtronic, Johnson & Johnson Services, Inc, Insulet Corporation, Tandem Diabetes Care, Inc, F. Hoffmann-La Roche Ltd, Beta Bionics, BIGFOOT BIOMEDICAL. INC, Dexcom, Inc., CCellnovo, Pancreum, Inc, TypeZero Technologies, Inc, SEMMA THERAPEUTICS, Defymed, Animas Corporation, Admetsys, Diabeloop.
Browse Related Reports:
Global Drug Screening Market By Products and Services (Immunoassay Analyzers, Chromatography, Breath Analyzers, Rapid Testing Devices, Assay Kits and Reagents), Sample Type (Urine, Breath, Saliva, Hair, Blood, Skin, Sweat)Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024.
Global Radiotherapy Market, By Type (Beam Radiotherapy (IGRT, IMRT, VMAT, Tomotherapy, 3D CRT, Proton Beam, Stereotactic), Brachytherapy (LDR, HDR), Systemic Radiotherapy), By Product Type (Cyberknife, Gammaknife, Linac, Proton Beam, Systemic Radiotherapy, Seeds, Afterloaders), By Indication (Prostate & Breast Cancer)), By Geography (North America, Europe, Asia Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024.
Global Molecular Spectroscopy Market, By Type (Nuclear Magnetic Resonance (Continuous Wave, Fourier Transform, Solid State), UV-Vis, Infrared (IR), Near Infrared (NIR), Colour Spectroscopy, Raman Spectroscopy, Others), By Applications (Pharmaceuticals, Biotech, Food and Beverages, Environmental Testing, Academics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Industry Trends and Forecast to 2024.
Global Leukemia Therapeutics Market, By Disease Type (Chronic Lymphatic Leukemia, Acute Lymphatic Leukemia), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Surgery), By Stages (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East & Africa)– Industry Trends and Forecast to 2025.
Global Artificial Pancreas Systems Market – Industry Trends & Forecast to 2026